Free Trial
NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

Xilio Therapeutics logo
$0.82 +0.02 (+2.25%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$0.82 +0.01 (+0.73%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Xilio Therapeutics Stock (NASDAQ:XLO)

Advanced

Key Stats

Today's Range
$0.79
$0.84
50-Day Range
$0.65
$0.86
52-Week Range
$0.62
$1.70
Volume
432,517 shs
Average Volume
944,316 shs
Market Capitalization
$42.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Moderate Buy

Company Overview

Xilio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

XLO MarketRank™: 

Xilio Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 753rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xilio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Xilio Therapeutics has a consensus price target of $3.00, representing about 266.7% upside from its current price of $0.82.

  • Amount of Analyst Coverage

    Xilio Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Xilio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.14) to ($0.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xilio Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xilio Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xilio Therapeutics has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Xilio Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    26.78% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 9.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently increased by 14.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Xilio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Xilio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    26.78% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 9.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently increased by 14.42%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Xilio Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    5 people have searched for XLO on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Xilio Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xilio Therapeutics' insider trading history.
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XLO Stock News Headlines

Capital Gains Tax Strategies for Seniors
Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.tc pixel
Xilio Therapeutics sees cash runway into 1Q27
See More Headlines

XLO Stock Analysis - Frequently Asked Questions

Xilio Therapeutics' stock was trading at $0.9550 at the start of the year. Since then, XLO shares have decreased by 14.3% and is now trading at $0.8180.

Xilio Therapeutics, Inc. (NASDAQ:XLO) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.08. The business earned $8.21 million during the quarter, compared to analyst estimates of $8.21 million. Xilio Therapeutics had a negative trailing twelve-month return on equity of 399.15% and a negative net margin of 374.79%.

Xilio Therapeutics (XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share.

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and atai Life Sciences (ATAI).

Company Calendar

Last Earnings
8/14/2025
Today
10/05/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XLO
CIK
1840233
Fax
N/A
Employees
70
Year Founded
2015

Price Target and Rating

High Price Target
$4.00
Low Price Target
$2.00
Potential Upside/Downside
+266.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$58.24 million
Net Margins
-374.79%
Pretax Margin
-374.79%
Return on Equity
-399.15%
Return on Assets
-58.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.32
Quick Ratio
2.32

Sales & Book Value

Annual Sales
$15.00 million
Price / Sales
2.83
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.40 per share
Price / Book
2.05

Miscellaneous

Outstanding Shares
51,828,000
Free Float
48,563,000
Market Cap
$42.40 million
Optionable
Not Optionable
Beta
-0.07

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:XLO) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners